The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Tue, 26th Oct 2021 19:06

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Yellow Cake PLC - Jersey-based investor in uranium - Plans to raise USD150 million through placing. Will fund purchase of three millions pounds of physical uranium. "The long term outlook for the uranium price remains strong, driven by the more positive demand outlook and on-going supply constraints, causing the supply deficit to grow every year. We continue to seek further opportunities for value accretive opportunistic uranium purchases at an attractive price," Chief Executive Officer Andre Liebenberg says.

----------

Mercia Asset Management PLC - West Midlands-based asset manager - Completes GBP1.8 million investment into new portfolio company Forensic Analytics Ltd, alongside GBP2.7 million backing by Mercia managed Northern VCTs. "Following this investment, Mercia holds an 8.9% fully diluted direct equity stake in Forensic Analytics, with the Northern VCTs holding a further 13.9% fully diluted equity stake," Mercia says.

----------

Tern PLC - investor focused on the internet of things - Says "significant business momentum" continues across principal portfolio firms. Device Authority Ltd investee launches KeyScaler Edge offering to address IoT security challenges. "In addition to new customer wins and repeat orders, Device Authority have recently entered into further distribution partnerships, including with Trusted Objects, a leading independent player in cybersecurity technologies for embedded systems and cloud device management platforms, and with Titan Automotive Solutions, a leading provider of car connectivity solutions with a global presence," Tern says. Tern owns 57% of Device Authority. Virtual reality focused investee FVRVS Ltd, meanwhile, wins deal with company previously using a competitor's product. InVMA Ltd sees "strong sales growth", while Wyld Networks AB "continued to make further significant progress following its IPO on the NASDAQ First North Growth Market in Stockholm".

----------

Path Investments PLC - Bingley, England-based natural resources investment company - Says longstop date for DG Innovate Ltd buy extended to December 31. "Path and its advisers continue to progress the proposed transaction," company says.

----------

Caerus Mineral Resources PLC - London-based exploration & resource development company - Says trenching of stockpiles at Troulli project finds "very high-grade visible copper mineralisation". Copper grades are "highly significant", based on semi-quantitative XRF analysis. "Samples have been collected and are ready for dispatch to the assay laboratory," Caerus says. Duplicate samples also sent to partner Jubilee Metals Group PLC for testwork.

----------

Petra Diamonds Ltd - London-based diamond miner - Says revenue in first quarter ended September 30 improves year-on-year to USD114.9 million from USD77.7 million a year earlier. Says output falls annually to 861,991 carats from 974,346 carats.

----------

IMC Exploration Group PLC - Dublin-based exploration company focused on Ireland - Says drillhole 21-3850-01 at West Avoca encounters "four zones of massive and semi massive sulphide mineralisation". Says 18.7 metre interval or zinc, lead and silver mineralisation found. "IMC plans that the drill programme will allow an independent resource calculation to be undertaken in addition to that already in place for the spoils' and tailings' project," IMC adds.

----------

Angus Energy PLC - oil & gas development company - Shares revised competent persons report at Saltfleetby gas field. Says conservative estimate, or P90, of future cashflows to Angus stands at GBP31.7 million. Mid-case, or P50, has it at GBP55.9 million. Angus adds: "In summary the report estimates production giving rise to gross field revenues, before costs on a mid-case basis of GBP230 million (previously GBP141 million) of which Angus's share is 51%."

----------

Oxford Metrics PLC - software company servicing infrastructure, life sciences, entertainment and engineering markets - Says motion measurement unit Vicon wins deal with volumetric content and virtual production firm Dimension Studios. "Vicon's tracking, of both rigid and full body subjects, will be used alongside Dimension Studio's volumetric and real-time development capabilities by leading visual effects company DNEG for several high-profile virtual production projects - including a major motion picture and a 10-hour TV series," Oxford Metrics says.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says third quarter sales "strong" at USD964,000. "Importantly, both the September and June 2021 quarters combined have delivered a record USD2.24 million in cash receipts from customers over the 6-month period, with increasing month on month sales generated from new key markets, such as the UK and Ireland," MGC adds.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Teams with University College London to research generation of immune cells from induced pluripotent stem cells as a potential cancer therapy. ReNeuron will provide UCL with the stem cells. Company adds: "Induced pluripotent stem cells can differentiate into any cell type found in the body, but unlike most iPSCs, ReNeuron's proprietary CTX-iPSCs carry the conditional immortalisation system incorporated into CTX. ReNeuron's CTX derived iPSC's are available as clinical grade material potentially allowing faster development of arising therapeutics and the company believes that its conditional immortalisation technology could allow the company to manufacture cost efficiently at scale to treat large numbers of patients providing 'off the shelf' cell therapies."

----------

Omni Egis PLC - debt financing solutions provider for small to medium-sized businesses - Says AQSE listing "not commercial for the company to raise funds at the current share price". Notes market capitalisation currently below liquid resources. Convenes general meeting on November 18 to vote on AQSE withdrawal.

----------

CATCo Reinsurance Opportunities Fund Ltd - invests in catastrophe reinsurance risks - Receives "substantial level of investor support" for Markel CATCo Investment Management Ltd-funded buyout. Markel is CATCo's manager.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.